Stocky turns companies like AbCellera Biologics Inc. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →AbCellera Biologics Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Shows how much money the company made and spent, helping you track if it's growing.
The company told investors how it performed in the last three months; important for tracking progress.
New partnership means the company has a chance to earn money developing medicines with a major pharma company.
New board members bring expertise and oversight; helps ensure company leaders make good decisions.
New research deal could generate revenue and help develop cancer treatments using the company's technology.
Voters approved new leaders and confirmed the accountant who checks the company's books, supporting governance.
Added experienced board member provides oversight and guidance for company management decisions.
Stocky reads AbCellera Biologics Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
AbCellera Biologics Inc.'s most recent tracked filing was a 10-Q on 5 Aug 2026: Q2 2026 quarterly financial results reported.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
This page is just a preview. Open the live, interactive version for the full picture:
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.